RxDoctor Payments Data

Anjana Chandran, MD

Hematology · Chicago, ILNPI 1902292253

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 36 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 17 manufacturers, the largest accounting for just 14.8% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for hematology clinicians in IL, where the typical reported total is $2,003.

$900in general payments, 2019–2025

Across 36 payments — averaging $24.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$133
  • AstraZeneca$131
  • Exelixis Inc.$95
  • UCB, Inc.$91
  • Seagen Inc.$74
  • Johnson & Johnson$60
  • plus $316 from 11 others

What the payments were for

  • Food & beverage$900100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$900 in reported general payments places this provider in the 40th percentile of 49 hematology providers in Illinois.

See all hematology providers in Illinois

Medicare billing

Part B allowed, 2024
$58,380
Medicare patients
185
Services billed
561

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban48$45,150
Imatinib Mesylate13$17,290
Anastrozole120$2,097
Hydroxyurea21$519
Acyclovir19$187
MethotrexateMethotrexate Sodium12$153
Levofloxacin18$153
Allopurinol12$70

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$13$45,15048 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 49 hematology providers in Illinois.

Other hematology in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →